Y-mAbs Therapeutics (NASDAQ:YMAB) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) issued its earnings results on Friday. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), RTT News reports. The business had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same quarter in the previous year, the business posted ($0.18) earnings per share. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.

Y-mAbs Therapeutics Stock Down 0.5 %

Shares of Y-mAbs Therapeutics stock traded down $0.07 on Friday, hitting $15.48. 580,428 shares of the company traded hands, compared to its average volume of 330,577. Y-mAbs Therapeutics has a 12-month low of $4.69 and a 12-month high of $20.90. The company has a market cap of $689.94 million, a PE ratio of -27.64 and a beta of 0.68. The company has a 50-day moving average price of $14.11 and a 200 day moving average price of $13.17.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at $449,514. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, COO Joris Wilms sold 5,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the transaction, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 100,000 shares of company stock worth $1,338,100. Corporate insiders own 22.50% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on YMAB. Morgan Stanley reduced their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Wedbush restated an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Finally, BMO Capital Markets cut their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.14.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.